The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
immunotherapy
multiple myeloma
qualitative research
treatment choices
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
22
12
2021
received:
27
08
2021
accepted:
10
01
2022
pubmed:
16
2
2022
medline:
23
11
2022
entrez:
15
2
2022
Statut:
ppublish
Résumé
Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve remission, relapse is common. As more treatment options become available for multiple myeloma (MM), it is important to understand patients' experiences of current and emerging therapies. This study aimed to better understand patient experiences with treatment and therapies for MM using qualitative interviews and patient-reported information (PRI) shared on social media. Semistructured qualitative interviews were conducted with adults with RRMM who resided in the United States. In addition to the interviews, PRI was collected from YouTube and a patient advocacy website. Key themes from the interviews and PRI were summarized, and illustrative quotes were extracted. Twenty participants were interviewed; 11 were female, and mean (standard deviation) age was 60 (7.0) years. The PRI included 14 posts and 19 unique contributors (10 were female). Similar treatment-related symptoms were reported in the interviews and PRI. Fatigue and pain were the most frequently reported symptoms while receiving treatment in both the interviews and PRI. These symptoms had a meaningful impact on health-related quality of life (HRQOL); being off treatment and returning to normal living was described as an ideal treatment outcome. Nearly all interview participants (n = 18) preferred a treatment that would allow for a treatment-free interval, if it had the same efficacy and safety profile as a continuous treatment. The symptom experience reported in this study is consistent with known RRMM symptoms and HRQOL impacts. Additionally, this study highlighted that patients' treatment expectations are changing relative to their past treatment experience. Individuals living with RRMM strongly desire therapies with a treatment-free interval and minimal impact on their HRQOL.
Sections du résumé
BACKGROUND
Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve remission, relapse is common. As more treatment options become available for multiple myeloma (MM), it is important to understand patients' experiences of current and emerging therapies.
AIMS
This study aimed to better understand patient experiences with treatment and therapies for MM using qualitative interviews and patient-reported information (PRI) shared on social media.
METHODS
Semistructured qualitative interviews were conducted with adults with RRMM who resided in the United States. In addition to the interviews, PRI was collected from YouTube and a patient advocacy website. Key themes from the interviews and PRI were summarized, and illustrative quotes were extracted.
RESULTS
Twenty participants were interviewed; 11 were female, and mean (standard deviation) age was 60 (7.0) years. The PRI included 14 posts and 19 unique contributors (10 were female). Similar treatment-related symptoms were reported in the interviews and PRI. Fatigue and pain were the most frequently reported symptoms while receiving treatment in both the interviews and PRI. These symptoms had a meaningful impact on health-related quality of life (HRQOL); being off treatment and returning to normal living was described as an ideal treatment outcome. Nearly all interview participants (n = 18) preferred a treatment that would allow for a treatment-free interval, if it had the same efficacy and safety profile as a continuous treatment.
CONCLUSION
The symptom experience reported in this study is consistent with known RRMM symptoms and HRQOL impacts. Additionally, this study highlighted that patients' treatment expectations are changing relative to their past treatment experience. Individuals living with RRMM strongly desire therapies with a treatment-free interval and minimal impact on their HRQOL.
Identifiants
pubmed: 35168299
doi: 10.1002/cnr2.1603
pmc: PMC9675381
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1603Informations de copyright
© 2022 Janssen Pharmaceuticals. Cancer Reports published by Wiley Periodicals LLC.
Références
J Pain Symptom Manage. 2013 Nov;46(5):671-80
pubmed: 23535325
Qual Life Res. 2020 Jun;29(6):1419-1431
pubmed: 31848847
Support Care Cancer. 2014 Feb;22(2):417-26
pubmed: 24122403
Mayo Clin Proc. 2017 Apr;92(4):578-598
pubmed: 28291589
BMC Cancer. 2016 Jul 07;16:427
pubmed: 27387201
PLoS One. 2018 Jun 20;13(6):e0198606
pubmed: 29924873
Haematologica. 2016 Apr;101(4):396-406
pubmed: 27033237
J Patient Rep Outcomes. 2020 Sep 1;4(1):74
pubmed: 32870420
Patient. 2011;4(1):11-7
pubmed: 21766890
BMJ Open. 2016 Apr 06;6(4):e010501
pubmed: 27053271
Patient Educ Couns. 2013 Sep;92(3):426-31
pubmed: 23899831
BMC Med. 2019 Jan 16;17(1):11
pubmed: 30646913
PLoS One. 2020 May 5;15(5):e0232076
pubmed: 32369511
Blood Adv. 2020 Feb 25;4(4):629-637
pubmed: 32074277
Blood Cancer J. 2021 Feb 18;11(2):40
pubmed: 33602913
J Gen Intern Med. 2011 Mar;26(3):287-92
pubmed: 20945113
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
PLoS One. 2017 Jul 26;12(7):e0181689
pubmed: 28746358
BMC Cancer. 2019 Mar 25;19(1):264
pubmed: 30909874
Cancer Rep (Hoboken). 2022 Nov;5(11):e1603
pubmed: 35168299
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514
BMC Med Res Methodol. 2018 Nov 21;18(1):148
pubmed: 30463515
Haematologica. 2015 Jun;100(6):704-5
pubmed: 26034111
J Family Med Prim Care. 2015 Jul-Sep;4(3):324-7
pubmed: 26288766